Oncotargets and Therapy Dovepress Micro-ribonucleic Acid 29b Inhibits Cell Proliferation and Invasion and Enhances Cell Apoptosis and Chemotherapy Effects of Cisplatin via Targeting of Dnmt3b and Akt3 in Prostate Cancer

Background Micro-ribonucleic acids (miRNAs) are crucial regulators in malignant tumors. miRNA-29b (miR-29b) has been identified as a tumor suppressor in prostate cancer (PCa). However, very few studies have investigated the effects of miR-29b in PCa, especially the mechanism and its association with chemotherapy. Our study aimed to explore the role and mechanism of miR-29b in PCa. Materials and methods The expression levels of miR-29b were detected in ten clinical PCa specimens and four different PCa cell lines through quantitative real-time polymerase chain reaction. After miR-29b mimics and inhibitors were successfully transfected into LNCaP, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was then used to investigate cell proliferation and cisplatin sensitivity of PCa cells. Cell cycle, cell apoptosis, and cell invasion were detected via flow cytometry, annexin V–fluorescein isothiocyanate labeling, and transwell assay, respectively. Based on bioinformatic methods, Western blot analysis, and dual-luciferase reporter assay, novel target genes of miR-29b were identified. Results miR-29b was downregulated in PCa tissues compared with matched adjacent nontumor tissues. In the androgen-independent PCa cell line (LNCaP-AI), the expression of miR-29b was much lower than the androgen-dependent PCa cell line (LNCaP). Subsequent studies showed that forced expression of miR-29b inhibited cell proliferation and cell invasion and induced cell apoptosis in PCa. Upregulation of miR-29b also enhanced the chemosensitivity of PCa cells to cisplatin. Moreover, we identified DNMT3b and AKT3 as novel target genes of miR-29b in PCa. Conclusion Taken together, the results showed that miR-29b plays a tumor-suppressive role in PCa. It inhibits cell biological behavior and enhances the chemotherapy effects of cisplatin through its involvement in epigenetic regulation and PI3K/AKT pathway.

[1]  R. Luong,et al.  Crosstalking between Androgen and PI3K/AKT Signaling Pathways in Prostate Cancer Cells* , 2014, The Journal of Biological Chemistry.

[2]  Jun Yu,et al.  microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway , 2014, Oncotarget.

[3]  N. Zaffaroni,et al.  miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. , 2014, Biochemical pharmacology.

[4]  S. Sultana,et al.  Involvement of epigenetics and microRNA-29b in the urethane induced inception and establishment of mouse lung tumors. , 2014, Experimental and molecular pathology.

[5]  Andrew H. Beck,et al.  Targeting Akt3 signaling in triple-negative breast cancer. , 2014, Cancer research.

[6]  furong dai,et al.  The anti-chemoresistant effect and mechanism of MUC1 aptamer-miR-29b chimera in ovarian cancer. , 2013, Gynecologic oncology.

[7]  Wei-Qiang Gao,et al.  Androgen receptor is negatively correlated with the methylation-mediated transcriptional repression of miR-375 in human prostate cancer cells , 2013, Oncology reports.

[8]  Fang Wang,et al.  The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia , 2013, Cell Death and Differentiation.

[9]  P. G. Rao,et al.  Mahanine restores RASSF1A expression by down-regulating DNMT1 and DNMT3B in prostate cancer cells , 2013, Molecular Cancer.

[10]  Cheng Huang,et al.  miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. , 2013, Toxicology.

[11]  M. Caligiuri,et al.  Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia , 2013, Leukemia.

[12]  V. Dolo,et al.  Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells. , 2013, Oncology reports.

[13]  Yang Wang,et al.  The role of miRNA-29 family in cancer. , 2013, European journal of cell biology.

[14]  David P. Bartel,et al.  Beyond Secondary Structure: Primary-Sequence Determinants License Pri-miRNA Hairpins for Processing , 2013, Cell.

[15]  C. Xiao,et al.  MicroRNA-221 Induces Cell Survival and Cisplatin Resistance through PI3K/Akt Pathway in Human Osteosarcoma , 2013, PloS one.

[16]  N. Munshi,et al.  miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 , 2012, Cell Death and Disease.

[17]  M. Negrini,et al.  DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma , 2012, Oncotarget.

[18]  J. Rantala,et al.  Distinct roles of AKT isoforms in regulating β1-integrin activity, migration, and invasion in prostate cancer , 2012, Molecular biology of the cell.

[19]  Peng Ru,et al.  miRNA-29b Suppresses Prostate Cancer Metastasis by Regulating Epithelial–Mesenchymal Transition Signaling , 2012, Molecular Cancer Therapeutics.

[20]  Yuefeng Yang,et al.  Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1. , 2011, Biochemical and biophysical research communications.

[21]  B. Zani,et al.  Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models. , 2011, Endocrinology.

[22]  R. Turner,et al.  Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma , 2011, Epigenetics.

[23]  V. Hogan,et al.  Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment , 2010, Cell Death and Disease.

[24]  K. Nakashiro,et al.  Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo. , 2010, Biochemical and biophysical research communications.

[25]  R. Ray,et al.  MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells. , 2010, Genes & cancer.

[26]  I. Weissman,et al.  microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia , 2010, The Journal of experimental medicine.

[27]  C. Bloomfield,et al.  MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. , 2009, Blood.

[28]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[29]  F. Slack,et al.  MicroRNA in cancer prognosis. , 2008, The New England journal of medicine.

[30]  W. Filipowicz,et al.  Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? , 2008, Nature Reviews Genetics.

[31]  C. Morrison,et al.  MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B , 2007, Proceedings of the National Academy of Sciences.

[32]  W. Filipowicz,et al.  Repression of protein synthesis by miRNAs: how many mechanisms? , 2007, Trends in cell biology.

[33]  W. Sellers,et al.  Akt-regulated pathways in prostate cancer , 2005, Oncogene.

[34]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.